Intriguingly, patients with low PD-L1-expressing (PD-L1low) tumor vaccines generated a higher memory CD8+ T cell response (45%, 9/20) than patients with PD-L1high tumor vaccine products (25%, 3/12) [88]. Here, CD8A is linked to neoplasm.